Effect of Pregabalin on Costs and Consequences in Patients with Refractory Severe Generalized Anxiety Disorder and Concomitant Severe Symptoms of Depression in Daily Medical Practice

Trial Profile

Effect of Pregabalin on Costs and Consequences in Patients with Refractory Severe Generalized Anxiety Disorder and Concomitant Severe Symptoms of Depression in Daily Medical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2011

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Generalised anxiety disorder; Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Jan 2011 New trial record
    • 09 Nov 2010 Results presented at the 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top